These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 30498338)

  • 1. What is the impact of GOLD 2017 recommendations in primary care? - a descriptive study of patient classifications, treatment burden and costs.
    Gayle A; Dickinson S; Morris K; Poole C; Mathioudakis AG; Vestbo J
    Int J Chron Obstruct Pulmon Dis; 2018; 13():3485-3492. PubMed ID: 30498338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
    Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
    Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.
    Price D; West D; Brusselle G; Gruffydd-Jones K; Jones R; Miravitlles M; Rossi A; Hutton C; Ashton VL; Stewart R; Bichel K
    Int J Chron Obstruct Pulmon Dis; 2014; 9():889-904. PubMed ID: 25210450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiology, severity, and treatment of chronic obstructive pulmonary disease in the United Kingdom by GOLD 2013.
    Raluy-Callado M; Lambrelli D; MacLachlan S; Khalid JM
    Int J Chron Obstruct Pulmon Dis; 2015; 10():925-37. PubMed ID: 25999708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics, disease burden and costs of COPD patients in the two years following initiation of long-acting bronchodilators in UK primary care.
    Punekar YS; Landis SH; Wurst K; Le H
    Respir Res; 2015 Nov; 16():141. PubMed ID: 26572740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2017 Global Initiative for Chronic Obstructive Lung Disease reclassifies half of COPD subjects to lower risk group.
    Högman M; Sulku J; Ställberg B; Janson C; Bröms K; Hedenström H; Lisspers K; Malinovschi A
    Int J Chron Obstruct Pulmon Dis; 2018; 13():165-173. PubMed ID: 29379281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cross-sectional survey of current treatment and symptom burden of patients with COPD consulting for routine care according to GOLD 2014 classifications.
    Ding B; Small M; Holmgren U
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1527-1537. PubMed ID: 28579771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD).
    Chalmers JD; Poole C; Webster S; Tebboth A; Dickinson S; Gayle A
    Respir Res; 2018 Apr; 19(1):63. PubMed ID: 29642882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis.
    Hertel N; Kotchie RW; Samyshkin Y; Radford M; Humphreys S; Jameson K
    Int J Chron Obstruct Pulmon Dis; 2012; 7():183-99. PubMed ID: 22500119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy.
    Palli SR; Zhou S; Shaikh A; Willey VJ
    J Manag Care Spec Pharm; 2021 May; 27(5):625-637. PubMed ID: 33779246
    [No Abstract]   [Full Text] [Related]  

  • 11. The cost-saving switch from inhaled corticosteroid-containing treatments to dual bronchodilation: a two-country projection of epidemiological and economic burden in chronic obstructive pulmonary disease.
    Souliotis K; Silva Miguel L; Hillas G; Borges M; Papageorgiou G; Viana D; Malhadeiro J; Soulard S
    Ther Adv Respir Dis; 2020; 14():1753466620926802. PubMed ID: 32519591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic impact of delaying initiation with multiple-inhaler maintenance triple therapy in Spanish patients with chronic obstructive pulmonary disease.
    Sicras Mainar A; Huerta A; Navarro Artieda R; Monsó E; Landis SH; Ismaila AS
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2121-2129. PubMed ID: 31571848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual versus triple therapy in patients hospitalized for COPD in France: a claims data study.
    Dalon F; Roche N; Belhassen M; Nolin M; Pegliasco H; Deslée G; Housset B; Devillier P; Van Ganse E
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1839-1854. PubMed ID: 31692478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD.
    Ke X; Marvel J; Yu TC; Wertz D; Geremakis C; Wang L; Stephenson JJ; Mannino DM
    Int J Chron Obstruct Pulmon Dis; 2016; 11():1689-703. PubMed ID: 27555759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status.
    de Miguel-Díez J; Carrasco-Garrido P; Rejas-Gutierrez J; Martín-Centeno A; Gobartt-Vázquez E; Hernandez-Barrera V; Gil de MA; Jimenez-Garcia R
    Lung; 2011 Jun; 189(3):199-206. PubMed ID: 21499887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR; Dilleen M; Morris K; Hills S; Emir B; Jones R
    Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacological cost of COPD during Greek economic crisis.
    Stafyla E; Kerenidi T; Gerogianni I; Geitona M; Daniil Z; Gourgoulianis KI
    Int J Chron Obstruct Pulmon Dis; 2017; 12():461-466. PubMed ID: 28203069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD).
    Rebordosa C; Plana E; Aguado J; Thomas S; García-Gil E; Perez-Gutthann S; Castellsague J
    Pharmacoepidemiol Drug Saf; 2019 Feb; 28(2):126-133. PubMed ID: 29740896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COPD management costs according to the frequency of COPD exacerbations in UK primary care.
    Punekar YS; Shukla A; Müllerova H
    Int J Chron Obstruct Pulmon Dis; 2014; 9():65-73. PubMed ID: 24426781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptomatic burden of COPD for patients receiving dual or triple therapy.
    Chen S; Small M; Lindner L; Xu X
    Int J Chron Obstruct Pulmon Dis; 2018; 13():1365-1376. PubMed ID: 29731624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.